EGFR and lung carcinoma: In patients with advanced or relapsed lung cancers, testing for the presence of epidermal growth factor receptor (EGFR)-sensitizing mutations 5 and the status of anaplastic lymphoma kinase (ALK) gene rearrangements prior to the use of tyrosine kinase inhibitors (TKIs) for therapy has substantially improved survival outcomes 6.